International Assets Investment Management LLC Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

International Assets Investment Management LLC grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 10,687.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 319,514 shares of the company’s stock after buying an additional 316,552 shares during the period. International Assets Investment Management LLC owned 0.08% of Moderna worth $21,353,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Commerzbank Aktiengesellschaft FI grew its stake in shares of Moderna by 9.7% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 6,087 shares of the company’s stock valued at $407,000 after buying an additional 537 shares during the period. Bank Pictet & Cie Europe AG lifted its holdings in shares of Moderna by 1.4% during the 3rd quarter. Bank Pictet & Cie Europe AG now owns 529,686 shares of the company’s stock valued at $35,399,000 after acquiring an additional 7,060 shares in the last quarter. Eastern Bank lifted its holdings in shares of Moderna by 2.3% during the 3rd quarter. Eastern Bank now owns 14,578 shares of the company’s stock valued at $974,000 after acquiring an additional 334 shares in the last quarter. Raymond James & Associates lifted its holdings in shares of Moderna by 19.7% during the 3rd quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock valued at $10,831,000 after acquiring an additional 26,657 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after acquiring an additional 574 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $55.22 on Wednesday. Moderna, Inc. has a twelve month low of $52.26 and a twelve month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $21.16 billion, a price-to-earnings ratio of -3.50 and a beta of 1.66. The business has a 50 day simple moving average of $66.97 and a 200-day simple moving average of $102.38.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. During the same period in the previous year, the business earned ($3.62) EPS. The business’s quarterly revenue was down 29.9% on a year-over-year basis. As a group, equities research analysts expect that Moderna, Inc. will post -9.88 earnings per share for the current year.

Insider Activity

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,184 shares of company stock worth $238,531. 15.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, September 13th. Barclays reduced their target price on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a report on Monday, September 16th. The Goldman Sachs Group reduced their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Finally, Sanford C. Bernstein began coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $94.65.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.